Dogwood Therapeutics, Inc. (DWTX) stock
DWTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.08+0.00 (0.00%)
Close on Nov 18, 2026Market cap $36.71MP/E –Yield –
Dogwood Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Dogwood Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$38.76M. For fiscal 2025 it was -$27.97M. The highest annual figure on record is -$5.45M in fiscal 2023.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$27.97M | – |
| FY2024 | Dec 31, 2024 | -$12.23M | – |
| FY2023 | Dec 31, 2023 | -$5.45M | – |
| FY2022 | Dec 31, 2022 | -$12.32M | – |
| FY2021 | Dec 31, 2021 | -$15.64M | – |
| FY2020 | Dec 31, 2020 | -$10.01M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$14.06M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.08M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.81M | – |
| Q3 FY2025 | Sep 30, 2025 | -$15.81M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.92M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.43M | – |
| Q4 FY2024 | Dec 31, 2024 | -$7.54M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.30M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.07M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.31M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.14M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.27M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.48M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.56M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.09M | – |
| Q3 FY2022 | Sep 30, 2022 | -$2.59M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.67M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.96M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.19M | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.11M | – |
| Q2 FY2021 | Jun 30, 2021 | -$4.28M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.06M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.42M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.66M | – |
| Q2 FY2020 | Jun 30, 2020 | -$538.38K | – |
| Q1 FY2020 | Mar 31, 2020 | -$382.55K | – |
See a number that looks wrong?